Key Account
Oncology / Hematology / Dermatology
Since 2023
Incyte Corporation
15-program portfolio spanning oncology, hematology, and dermatology — active 2026 programs with 650K+ deterministically matched HCPs across three distinct NPI universes.
Programs
Niktimvo · Chronic GvHD
Niktimvo GVHD 2026Active
Chronic Graft-vs-Host Disease · Nov 2025–Dec 2026
Multi-channel HCP campaign across LinkedIn AN, Meta, LinkedIn, and Reddit. 266,876 verified HCP impressions delivered through April at 79.5% NPI match. $804,993 total investment.
Active · $804,993
Niktimvo GVHD 2025Complete
Chronic Graft-vs-Host Disease · 2024–Apr 2026
Year-one Niktimvo awareness program, now complete. $781,167 delivered across LinkedIn, Meta, and Reddit establishing baseline HCP reach for the cGVHD franchise.
Complete · $781,167
Jakafi · Hematology-Oncology
Jakafi MPNUnder-Pacing
Myeloproliferative Neoplasms
NPI-targeted HCP education for MPN prescribers on LinkedIn and Meta. Currently pacing below target — delivery review underway to assess acceleration options.
Under-Pacing
Jakafi GVHDActive
Chronic Graft-vs-Host Disease
HCP engagement for the Jakafi cGVHD indication. Shares a near-identical transplant hematologist NPI list with Niktimvo — enabling zero-cost audience sequencing across both GvHD brands.
Active · LinkedIn · Meta
Opzelura · Dermatology
Opzelura ADUnder-Pacing
Atopic Dermatitis
Dermatologist-targeted awareness program for the AD indication on LinkedIn and Meta. Pacing below target — reallocation review underway.
Under-Pacing
Opzelura VITUnder-Pacing
Vitiligo
Vitiligo-focused HCP program targeting dermatologists on LinkedIn and Meta. Shares audience infrastructure with Opzelura AD for cross-indication efficiency.
Under-Pacing
Opzelura HCP AccessActive
Market Access · HCP Education
Market access education program supporting formulary pull-through and prescription access for the Opzelura portfolio across dermatology practices.
Active · LinkedIn · Meta
Monjuvi · Hematology-Oncology (Lymphoma)
Monjuvi 2L DLBCLActive
Diffuse Large B-Cell Lymphoma · 2nd Line
2nd-line DLBCL hematologist program on LinkedIn and Meta. Targeting hematology-oncology specialists with NPI-verified impressions.
Active
Monjuvi 2L FLActive
Follicular Lymphoma · 2nd Line
Follicular Lymphoma 2nd-line program. Active delivery targeting hematology-oncology specialists on LinkedIn and Meta.
Active
Monjuvi 1L DLBCLActive
Diffuse Large B-Cell Lymphoma · 1st Line
1st-line DLBCL program. Active delivery reaching hematology-oncology specialists. Part of Monjuvi's multi-indication LinkedIn and Meta strategy.
Active
Zynyz · GI Oncology (SCAC)
Zynyz 2025At Risk
Squamous Cell Anal Carcinoma · ends Jul 1, 2026
SCAC awareness program ending July 1. Approximately 49% of budget unspent — immediate LinkedIn pacing acceleration required to meet delivery targets before close.
Deadline July 1
Zynyz 2026Active
Squamous Cell Anal Carcinoma · 2026
Zynyz SCAC continuation program for 2026. Active delivery on LinkedIn and Meta targeting GI oncologists and oncology specialists.
Active · LinkedIn · Meta
Dermatology · Oncology · Portfolio
POVO HS TruthsPaused
Hidradenitis Suppurativa · Povorcitinib
Portfolio's top-performing CTR at 0.55% before LinkedIn pause on 3/31. Execution transitioning to Deerfield — reactivation pending. Every week of inactivity risks cumulative delivery shortfall.
Deerfield Transition
PemazyreUnder-Pacing
Cholangiocarcinoma · GI Oncology
Cholangiocarcinoma HCP program targeting GI oncologists and hepatobiliary surgeons on LinkedIn and Meta. Currently pacing below target.
Under-Pacing
Medical AffairsActive
Portfolio · HCP Education
Portfolio-level medical affairs program supporting HCP education and engagement across the full Incyte brand portfolio using shared NPI infrastructure.
Active · Multi-Brand
Growth Opportunities
Reactivate POVO via DeerfieldAction Needed
Transition — Urgent
POVO HS Truths had the portfolio's top CTR (0.55%) before LinkedIn paused 3/31. Transitioning execution to Deerfield preserves this program's momentum. Every week of inactivity reduces cumulative impression delivery vs plan and risks a full budget shortfall.
Accelerate Zynyz 2025Action Needed
~49% Budget Unspent
Zynyz 2025 (#1324) ends July 1, 2026. Immediate LinkedIn pacing acceleration is required. A delivery shortfall on Zynyz 2025 impacts the Zynyz 2026 activation timeline and the overall Incyte relationship.
Deadline July 1
Reddit for Rare Disease$30K–$60K
+20% incremental rare disease reach
Hematologists and transplant specialists are among Reddit's most active HCP communities. Jakafi MPN already includes Reddit — extending to Niktimvo GVHD 2026 and Pemazyre adds incremental reach to a highly engaged rare disease audience at low CPM.
Available Now
Jakafi → Niktimvo SequencingNo added cost
Shared GvHD HCP universe
Jakafi GVHD and Niktimvo GVHD share a near-identical transplant hematologist NPI list. Sequencing Jakafi-engaged HCPs into Niktimvo messaging — or vice versa — is enabled within the same NPI infrastructure at no incremental list cost.
Enable Now